Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), 2022 | 105 | 2022 |
Phase I/II study of LAG525±spartalizumab (PDR001) in patients (pts) with advanced malignancies. DS Hong, P Schoffski, A Calvo, J Sarantopoulos, M Ochoa De Olza, ... Journal of Clinical Oncology 36 (15_suppl), 3012-3012, 2018 | 73 | 2018 |
Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071 S Piperno-Neumann, J Larkin, RD Carvajal, JJ Luke, GK Schwartz, ... Molecular cancer therapeutics 19 (4), 1031-1039, 2020 | 54 | 2020 |
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors K Conlon, DC Watson, TA Waldmann, A Valentin, C Bergamaschi, ... Journal for immunotherapy of cancer 9 (11), 2021 | 31 | 2021 |
Using visual statistical inference to better understand random class separations in high dimension, low sample size data N Roy Chowdhury, D Cook, H Hofmann, M Majumder, EK Lee, AL Toth Computational Statistics 30, 293-316, 2015 | 18 | 2015 |
Mind reading: Using an eye-tracker to see how people are looking at lineups. Y Zhao, D Cook, H Hofmann, M Majumder, NR Chowdhury International Journal of Intelligent Technologies & Applied Statistics 6 (4), 2013 | 13 | 2013 |
Visual mining methods for RNA-Seq data: data structure, dispersion estimation and significance testing T Yin, M Majumder, NR Chowdhury, D Cook, R Shoemaker, M Graham Journal of Data Mining in Genomics & Proteomics 4 (139), 137, 2013 | 13 | 2013 |
387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies CC Lin, E Garralda, P Schöffski, D Hong, L Siu, M Martin, M Maur, R Hui, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 12 | 2020 |
nullabor: Tools for graphical inference H Wickham, NR Chowdhury, D Cook R package version 0.2 1, 213, 2012 | 12 | 2012 |
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies CC Lin, E Garralda, P Schöffski, DS Hong, LL Siu, M Martin, M Maur, ... Oncoimmunology 13 (1), 2290787, 2024 | 7 | 2024 |
Utilizing distance metrics on lineups to examine what people read from data plots NR Chowdhury, D Cook, H Hofmann, M Majumder, Y Zhao arXiv preprint arXiv:1408.1889, 2014 | 6 | 2014 |
Where’s Waldo: Looking closely at a lineup NR Chowdhury, D Cook, H Hofmann, M Majumder, Y Zhao Technical Report 2, Iowa State University, Department of Statistics,, 2012 | 6 | 2012 |
Abstract CT082: phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors K Conlon, R Leidner, D McNeel, S Gupta, A Wang-Gillam, TA Waldmann, ... Cancer Research 79 (13_Supplement), CT082-CT082, 2019 | 3 | 2019 |
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic … R Leidner, A Wang-Gillam, S Gupta, R Wesolowski, D McNeel, K Conlon, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 2 | 2020 |
Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178)+ spartalizumab … CC Lin, M Joerger, P Grell, AA Chiappori, TA Leal, S Kasper, G Jerusalem, ... European Journal of Cancer 138, S12-S13, 2020 | 2 | 2020 |
Measuring lineup difficulty by matching distance metrics with subject choices in crowd-sourced data NR Chowdhury, D Cook, H Hofmann, M Majumder Journal of Computational and Graphical Statistics 27 (1), 132-145, 2018 | 2 | 2018 |
Explorations of the lineup protocol for visual inference: application to high dimension, low sample size problems and metrics to assess the quality N Roy Chowdhury | 1 | 2014 |
Package ‘nullabor’ H Wickham, NR Chowdhury, D Cook, H Hofmann | | 2024 |
A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab+ relatlimab fixed-dose combination in previously untreated … GV Long, R Gutzmer, A Haydon, EM Couselo, C Lebbé, M Carlino, ... EJC Skin Cancer 2, 2024 | | 2024 |
nullabor: tools for graphical inference Wickham H, Chowdhury NR, Cook D, Hofmann H R package version 0.3.5, 2018 | | 2018 |